Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06182267 · ClinicalTrials.gov registry record · Phase 1
Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101
A Phase 1 study, sponsored by Colgate Palmolive.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT06182267 is a Phase 1 study that has completed, run by Colgate Palmolive. The registered enrollment target is 29 participants.
The verdict
NCT06182267, a Phase 1 study, has completed, sponsored by Colgate Palmolive.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
Pharmacokinetic (PK) study of L-arginine after exaggerated oral use of the novel dentifrice product COL101 after repeated daily applications in healthy adult subjects.
Interventions
- DRUG L Arginine
- DRUG Sodium Fluoride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2023-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06182267
The ClinicalTrials.gov registry entry for NCT06182267 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Colgate Palmolive, which has 51 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which L Arginine is the first listed.
NCT06182267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06182267 about?
NCT06182267 is a clinical study titled "Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101". Pharmacokinetic (PK) study of L-arginine after exaggerated oral use of the novel dentifrice product COL101 after repeated daily applications in healthy adult subjects.
What is the current status of trial NCT06182267?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2023-11-27. Estimated completion is 2023-12-22.
What interventions are being tested in trial NCT06182267?
The interventions under investigation include: L Arginine (DRUG), Sodium Fluoride (DRUG).
Who is sponsoring clinical trial NCT06182267?
This trial is sponsored by Colgate Palmolive, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.